Private firm Procept Biorobotics Corp. netted $118 million in equity financing from new and existing investors to globally commercialize its minimally invasive Aquablation technology to treat benign prostatic hyperplasia (BPH). The funding was led by Viking Global Investors LP, and included Perceptive Advisors and CPMG Inc., new and returning investors, respectively. The company garnered $52 million in earlier funding rounds, totaling $170 million raised so far.